M. Rebsamen

Genetic polymorphisms and drug interactions modulating CYP 2 D 6 and CYP 3 A activities have a major effect on oxycodone analgesic efficacy and safetybph

D. Hochstrasser, Y. Daali, P. Dayer, 2010 .

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

D. Hochstrasser, Y. Daali, P. Dayer, 2010, British journal of pharmacology.

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

D. Hochstrasser, Y. Daali, P. Dayer, 2010, British journal of pharmacology.

Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection

Y. Daali, F. Negro, D. Moradpour, 2012, Journal of viral hepatitis.

Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots

Y. Daali, P. Dayer, B. Walder, 2014, Clinical pharmacology and therapeutics.

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

D. Hochstrasser, Y. Daali, P. Dayer, 2009, The Pharmacogenomics Journal.

Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot

Y. Daali, P. Dayer, J. Déglon, 2012, Clinical pharmacology and therapeutics.